Dolutegravir/Lamivudine and Phenytoin Interaction

Understanding the Dolutegravir/Lamivudine and Phenytoin Interaction

FDA-approved prescribing information for these two drugs flags their combination as a moderate-severity interaction. Dolutegravir/Lamivudine belongs to the Integrase Inhibitor / NRTI Combination class and Phenytoin belongs to the Anticonvulsant (Hydantoin) class - two categories that can collide when co-prescribed. The mechanism described in FDA labeling is: Phenytoin causes your body to clear dolutegravir more quickly, which reduces the amount of medicine available to fight the virus. Severity tiers matter: major flags generally advise avoidance, moderate flags often require monitoring or dose adjustment, and minor flags may only call for awareness.

Context around a specific patient determines real-world impact. Dolutegravir/Lamivudine has 9 total documented interactions on file in this dataset, and Phenytoin has 147. Each additional medication compounds the interaction surface, which is why pharmacists run full-profile checks rather than evaluating one pair at a time. FDA-derived guidance for this pair is: Avoid using these drugs at the same time since there are no clear instructions on how to adjust the dosage safely. Timing of doses, renal and hepatic function, age, and other concurrent prescriptions all shape whether a labeled interaction matters clinically.

An interaction flag is not a verdict. A large share of labeled interactions are managed routinely in clinical practice, the fix may be as simple as spacing doses or adding a monitoring test. Others require the prescriber to choose a different medication entirely. This page surfaces FDA-sourced labeling and openFDA data for educational purposes only; it is not medical advice and cannot account for your full clinical picture. Never start, stop, or adjust either Dolutegravir/Lamivudine or Phenytoin based on a web page, speak with your prescriber or pharmacist before making any change.